Patient perspective on Zanamivir in the treatment of influenza

International Journal of Clinical Practice

Volumn 56, Issue 1, 2002, Pages 7-10

  Bricaire, F ^a   Cohen, J M ^a   Jacquet, M ^a   Boucot, I ^a   Nicolas, M ^a   Begue P ^a   Carrat, F ^a   Freymouth, F ^a   Housset, B ^a   Manuguerra, J C ^a   Olivier, C ^a   Pappo, M ^a   Veyssier, P ^a  

^a GLAXOSMITHKLINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PLACEBO; ZANAMIVIR;

AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; COUGHING; FEMALE; FEVER; FRANCE; HEADACHE; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MAJOR CLINICAL STUDY; MALE; MYALGIA; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHARMACIST; PRIORITY JOURNAL; QUESTIONNAIRE; SYMPTOMATOLOGY;

AGED; ANTIVIRAL AGENTS; FEMALE; FRANCE; GUANIDINES; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; PYRANS; SIALIC ACIDS; TREATMENT OUTCOME; ZANAMIVIR;

EID: 0036151491     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. L'impact médico-économique de la grippe. Enquête GEIG - Open Rome. 12èmes Rencontres Européens sur la grippe et sa prévention
2. 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro
3. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers
4. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal dosing in healthy volunteers
5. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections
6. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: A randomized, double-blind, placebo-controlled European study
7. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections
8. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections
9. Randomized, placebo-controlled studies of inhaled zanamovir in the treatment of influenza A and B: Pooled efficacy analysis
10. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults
11. Zanamivir, a new targeted therapy in the treatment of influenza: A patient perspective assessed by questionnaire
12. Zanamivir for the treatment of clinically diagnosed influenza in clinical practice: Results of the valuable-insights-from-patients study
13. The efficacy of influenza vaccination in elderly individuals: A randomized double-blind placebo-controlled trial